Patient selection
Patients age > 18 at the time of rHGG diagnosis (WHO grade IV GBM or WHO grade III anaplastic astrocytoma) treated with concurrent ICI+SBRT or ICI monotherapy at New York-Presbyterian Hospital between 1/1/16 to 1/1/19 were included for analysis. This study was approved by the Weill Cornell Medicine Institutional Review Board. Demographic data, tumor pathological characteristics and profiling from available Foundation studies, radiology variables (tumor size, perfusion/diffusion metrics, and RT necrosis), prior treatments, AE’s attributable to treatment, PFS and OS following concurrent ICI + SBRT were collected. Survival data was obtained from available medical records.